Mucronulatol from Caribbean propolis exerts cytotoxic effects on human tumor cell lines

被引:0
作者
Diaz-Carballo, D. [1 ]
Freistuehler, M. [2 ]
Malak, S. [3 ]
Bardenheuer, W. [3 ]
Reusch, H. P. [1 ]
机构
[1] Ruhr Univ Bochum, Klin Pharmakol Abt, D-44801 Bochum, Germany
[2] Univ Klinikum Essen, Klin Augenheilkunde, Essen, Germany
[3] Univ Klinikum Essen, Innere Klin & Poliklin, Essen, Germany
关键词
flavonoids; mucronulatol; Indigofera sp; antitumoral activity; propolis; cell cycle;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Mucronulatol is one of the most cytotoxic substances present in Caribbean propolis. This work aimed at initially characterizing the biological effects of mucronulatol in cancer cell lines comprehending both wildtype and resistant sublines. Materials and methods: An RP-HPLC technique was employed to separate and purify mucronulatol. IC50 values were determined using the sulforhodamine B (SRB) proliferation assay. FACS-based cell cycle studies were carried out combining propidium, iodide staining and 5-bromo-2'-deoxyuridine incorporation. Cell cycle regulator proteins were detected by Western blotting. The transcription of genes of interest was analyzed using RT-PCR. Results: In MDR1-/MDR3+ cells, mucronulatol exhibited cytotoxicity in the range of 2.7 - 10.2 mu g/ml, while no cytotoxic effects were observed in MDR1+ systems at up to 100 mu g/ml. Cytometric studies revealed that mucronulatol promoted a global reduction in all cell cycle phases, with a remarkable increase of the apoptotic sub-G1 population. Immunoblotting showed that mucronulatol induced an up-regulation of p21(Cip1) and p27(Kip1) while down-regulating cyclin E and CDK4 in a drug concentration-dependent manner. No effect on topoisomerase I was observed, while we detected an altered expression of topoisomerases II-alpha/beta. RT-PCR studies showed that 2-fold the IC50 in HCT8 colon carcinoma cells was sufficient for altering the expression pattern of genes in this cell line, including topoisomerase 1, thymidilate synthase, EGF receptor and c-myc, amongst others. Conclusion: Here, we demonstrate for the first time that mucronulatol exerts cytotoxicity in cancer cell lines by targeting the control of cell cycle progression, indicating that the mechanism of action of this compound involves interference with the cell cycle machinery.
引用
收藏
页码:226 / 235
页数:10
相关论文
共 35 条
[1]   Cytotoxic activity of flavone glycoside from the stem of Indigofera aspalathoides Vahl [J].
Balasubramanian, Rajkapoor ;
Narayanan, Murugesh ;
Kedalgovindaram, Lalitha ;
Rama, Krishna Devarakonda .
JOURNAL OF NATURAL MEDICINES, 2007, 61 (01) :80-83
[2]   Differential responses of skin cancer-chemopreventive agents silibinin, quercetin, and epigallocatechin 3-gallate on mitogenic signaling and cell cycle regulators in human epidermoid carcinoma A431 cells [J].
Bhatia, N ;
Agarwal, C ;
Agarwal, R .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2001, 39 (02) :292-299
[3]   Regulation of p21cip1 expression by growth factors and the extracellular matrix reveals a role for transient ERK activity in G1 phase [J].
Bottazzi, ME ;
Zhu, XY ;
Böhmer, RM ;
Assoian, RK .
JOURNAL OF CELL BIOLOGY, 1999, 146 (06) :1255-1264
[4]   Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity [J].
Brusselmans, K ;
Vrolix, R ;
Verhoeven, G ;
Swinnen, JV .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (07) :5636-5645
[5]   Topoisomerase II inhibition and high yield of endoreduplication induced by the flavonoids luteolin and quercetin [J].
Cantero, G. ;
Campanella, C. ;
Mateos, S. ;
Cortes, F. .
MUTAGENESIS, 2006, 21 (05) :321-325
[6]   Luteolin, an emerging anti-cancer flavonold, poisons eukaryotic DNA topoisomerase I [J].
Chowdhury, AR ;
Sharma, S ;
Mandal, S ;
Goswami, A ;
Mukhopadhyay, S ;
Majumder, HK .
BIOCHEMICAL JOURNAL, 2002, 366 (02) :653-661
[7]   Pharmacogenomics of thymidylate synthase in cancer treatment [J].
Danenberg, PV .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 :2484-2494
[8]   PHASE-I AND PHARMACOLOGY STUDY OF FLAVONE ACETIC-ACID ADMINISTERED 2 OR 3 TIMES WEEKLY WITHOUT ALKALINIZATION [J].
DEFORNI, M ;
CHABOT, GG ;
ARMAND, JP ;
GOUYETTE, A ;
KLINKALAK, M ;
RECONDO, G .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (03) :219-224
[9]  
Ferry DR, 1996, CLIN CANCER RES, V2, P659
[10]   DISPOSITION OF QUERCETIN IN MAN AFTER SINGLE ORAL AND INTRAVENOUS DOSES [J].
GUGLER, R ;
LESCHIK, M ;
DENGLER, HJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1975, 9 (2-3) :229-234